Great to have my @OMERACT irAE group co-chair and friend @MarieKostine remind #EULAR2021 of the EULAR points to consider for irAEs - still relevant in a fast-moving field! available here in full @ARD_BMJ: https://t.co/wFZqKsdDoz in the Oncorheumatology session @RheumNow https://t.co/RuhIlkFRgM

• https://ard.bmj.com/content/80/1/36

I remember when we used to teach residents how to differentiate RA & PsA patients on imaging from normal scans. Give the right computer a whole lot of HR-pQCT scans, and it probably can do as well as the teaching rheumatologist... @LkasDer @maier_ak OP0145 #EULAR2021 @RheumNow https://t.co/kFx3oKzWKc

All credit to the @karolinskainst @Rigshospitalet @WH_Rheumatology investigators for: - tackling this issue - bringing it to #EULAR2021 - acknowledging limitations publicly & graciously 😊 It's... complicated. But each time we get closer! OP0210 https://t.co/2L3RDH276v @RheumNow https://t.co/UtcTukt3r8

• https://ard.bmj.com/content/80/Suppl_1/126

We know dementia (which is a/w inflammation) used to be a problem for RA pts. What's happened with that as we've got better at treating RA? Not only has dementia in RA pts decreased over time, the gap with non-RA pts has completely closed! @KronzerMD OP0216 #EULAR2021 @RheumNow https://t.co/bbbnQtv4vE

The advantage of the #EULAR2021 portal - the motivated speaker can answer all the excellent questions that the chairs don't ask! @RheumNow https://t.co/hewk02lFfM

We keep on advancing in rheumatology but some things stay the same: Our RA pts are stuck with multimorbidity more than other pts, esp for the women (➡️depression, hypothyroid, T2DM, lung dx) How can we support all of our pts needs better? @MayoClinic OP0213 #EULAR2021 @RheumNow https://t.co/0Y96Xa0fi2

I don’t care if we’re virtual, and not actually in Paris. It’s #EULAR2021 and no-one’s going to stop me from getting my French cheese @RheumNow https://t.co/w3Juvz5hfc

with TNFi therapy in RA: new ANA seroconversion is common (75%) TNFi-induced lupus is rare and mild (in this cohort of ANA/dsDNA neg RA pts from Porto) so don't be tempted to serially check the ANA with TNFi Rx! Let's put this rare habit to bed POS0204 #EULAR2021 @RheumNow https://t.co/5da34Ya3Xp

Which confers greater CV risk: - RA dx in early 2000s - T2DM dx c. 1990? The answer may surprise you. Amsterdam POS0213 #EULAR2021 @RheumNow https://t.co/SGsgKHf61U

Immunogenicity makes a difference for mAbs like TNF inhibitors. from Bart van den Bemt #EULAR2021 @RheumNow https://t.co/38ImlXdwUp

So where might mAb therapeutic drug monitoring have the most value for us, going forward? Proactive testing not at the moment (e.g. NOR-DRUM-A) but plenty of opportunities still exist! 6/ @MeghnaJani #EULAR2021 @RheumNow https://t.co/W5JATFHLfx

So what might therapeutic drug monitoring (TDM) be able to do for you? 1/ @MeghnaJani #EULAR2021 @RheumNow https://t.co/f6x4JAE5pQ

oh wait! no photos, but NOR-DRUM B results: Proactive TDM for dose optimisation during infliximab maintenance - proportion pts w/o dx worsening: TDM better by 15% - flare risk 2x with standard care vs TDM - benefit across diseases (incl RA) & subgroups Wow. #EULAR2021 @RheumNow https://t.co/nTAuKE2ZJa

Prof. Alten outlined the value of patient-reported outcomes for clinical practice! How do you collect patient-reported outcomes - PRO - in your rheumatology clinic? #EULAR2021 @RheumNow

#OP0145 Using a mixture of > 300 individuals with RA PsA or healthy the analyses via neural networks of HR-pQCT can differentiate the diagnosis assessing the bone surface with an accuracy of 89% #EULAR2021 @RheumNow